U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C30H30N2O7
Molecular Weight 530.5684
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PELIGLITAZAR

SMILES

COC1=CC=C(OC(=O)N(CC(O)=O)[C@@H](C)C2=CC=C(OCCC3=C(C)OC(=N3)C4=CC=CC=C4)C=C2)C=C1

InChI

InChIKey=CUADMYMMZWFUCY-FQEVSTJZSA-N
InChI=1S/C30H30N2O7/c1-20(32(19-28(33)34)30(35)39-26-15-13-24(36-3)14-16-26)22-9-11-25(12-10-22)37-18-17-27-21(2)38-29(31-27)23-7-5-4-6-8-23/h4-16,20H,17-19H2,1-3H3,(H,33,34)/t20-/m0/s1

HIDE SMILES / InChI
Molecular Formula C30H30N2O7
Molecular Weight 530.5684
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Peliglitazar (also known as BMS 426707-01), a dual α/γ peroxisome proliferator-activated receptor agonist, has been studied in phase I/II clinical trial in patients with type 2 diabetes mellitus. However, this study was discontinued.

Originator

Approval Year

Unknown
139594
PubMed

PubMed

TitleDatePubMed
Metabolism and disposition of 14C-labeled peliglitazar in humans.
2011 Feb
Patents

Patents

20030069275
1
20030087935
1
20030096846
1
20040147560
1
20040171644
1
20050119311
1

Sample Use Guides

In Vivo Use Guide
10 healthy male subjects with and without bile collection (groups 1 and 2) after a single 10-mg oral dose
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:52:31 GMT 2023
Edited
by admin
on Sat Dec 16 16:52:31 GMT 2023
Record UNII
D26ZN076H1
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PELIGLITAZAR
INN   USAN  
USAN   INN  
Official Name English
[[(4-Methoxyphenoxy)carbonyl][(1S)-1-[4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenyl]ethyl]amino]acetic acid
Systematic Name English
PELIGLITAZAR [USAN]
Common Name English
BMS-426707-1
Code English
peliglitazar [INN]
Common Name English
GLYCINE, N-((4-METHOXYPHENOXY)CARBONYL)-N-((1S)-1-(4-(2-(5-METHYL-2-PHENYL-4-OXAZOLYL)ETHOXY)PHENYL)ETHYL)-
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C98233
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
Code System Code Type Description
INN
8579
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
FDA UNII
D26ZN076H1
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
USAN
QQ-26
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
MESH
C557782
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104978
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
SMS_ID
300000034318
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
PUBCHEM
6451147
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
EPA CompTox
DTXSID20186830
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
CAS
331744-64-0
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
NCI_THESAURUS
C98154
Created by admin on Sat Dec 16 16:52:34 GMT 2023 , Edited by admin on Sat Dec 16 16:52:34 GMT 2023
PRIMARY
Related Record Type Details
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA
TARGET -> AGONIST
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA
TARGET -> AGONIST
Structure of PELIGLITAZAR
EXCRETED UNCHANGED
Parent compound in urine was also a minor component.
TRACE
URINE
Structure of PELIGLITAZAR
EXCRETED UNCHANGED
Unchanged drug in feces accounted for approximately 47% of the dose in group 1 and 18.4% in group 2.
FECAL
Related Record Type Details
Structure of 9-HYDROXY PELIGLITAZAR
METABOLITE -> PARENT
TRACE
URINE
Structure of 2-(((1S)-1-(4-HYDROXYPHENYL)ETHYL)-(4-METHOXYPHENOXY)CARBONYL-AMINO)ACETIC ACID
METABOLITE -> PARENT
4.38% of dose in group 1 and 1.79% of the dose in group 2
MAJOR
FECAL
Structure of 12-HYDROXY PELIGLITAZAR
METABOLITE -> PARENT
6.66% of dose in group 1 and 2.15% of the dose in group 2
FECAL
Structure of 2-(((1S)-1-(4-HYDROXYPHENYL)ETHYL)-(4-METHOXYPHENOXY)CARBONYL-AMINO)ACETIC ACID
METABOLITE -> PARENT
PLASMA; URINE
Structure of 12-HYDROXY O-DEMETHYL PELIGLITAZAR
METABOLITE -> PARENT
TRACE
URINE
Structure of 12-HYDROXY O-DEMETHYL PELIGLITAZAR
METABOLITE -> PARENT
6.13% of dose in group 1 and 2.33% of the dose in group 2
FECAL
Structure of 17-HYDROXY PELIGLITAZAR
METABOLITE -> PARENT
TRACE
URINE
Structure of O-DEMETHYL PELIGLITAZAR ACYL-BETA-D-GLUCURONIDE
METABOLITE -> PARENT
TRACE
URINE
Structure of 5-METHYL-2-PHENYL-4-OXAZOLEACETIC ACID
METABOLITE -> PARENT
MINOR
FECAL; URINE
Structure of 9-HYDROXY O-DEMETHYL PELIGLITAZAR
METABOLITE -> PARENT
TRACE
URINE
Structure of PELIGLITAZAR ACYL-BETA-D-GLUCURONIDE
METABOLITE -> PARENT
MAJOR
PLASMA
Structure of 17-HYDROXY PELIGLITAZAR
METABOLITE -> PARENT
0.88% of dose in group 1 and 0.90% of the dose in group 2
FECAL
Structure of 12-HYDROXY PELIGLITAZAR
METABOLITE -> PARENT
TRACE
URINE
Structure of PELIGLITAZAR ACYL-BETA-D-GLUCURONIDE
METABOLITE -> PARENT
MINOR
URINE
Structure of 9-HYDROXY O-DEMETHYL PELIGLITAZAR
METABOLITE -> PARENT
1.23% of dose in group 1
MINOR
FECAL
Structure of O-DEMETHYL PELIGLITAZAR
METABOLITE -> PARENT
14.6% of dose in group 1 and 4.66% of the dose in group 2
FECAL
Structure of OXAZOLE RING-OPENED PELIGLITAZAR
METABOLITE -> PARENT
5.52% of dose in group 1 and 1.63% of the dose in group 2
FECAL
Structure of 9-HYDROXY PELIGLITAZAR
METABOLITE -> PARENT
1.58% of dose in group 1
FECAL
Related Record Type Details
Structure of PELIGLITAZAR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC SINGLE DOSE

ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC ORAL ADMINISTRATION

SINGLE DOSE

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966